Your browser doesn't support javascript.
loading
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.
Harder, J; Ihorst, G; Heinemann, V; Hofheinz, R; Moehler, M; Buechler, P; Kloeppel, G; Röcken, C; Bitzer, M; Boeck, S; Endlicher, E; Reinacher-Schick, A; Schmoor, C; Geissler, M.
Affiliation
  • Harder J; Medizinische Klinik II, Hegau- Bodensee Klinikum, Virchowstraße 10, D-78224 Singen, Germany. jan.harder@hbh-kliniken.de
Br J Cancer ; 106(6): 1033-8, 2012 Mar 13.
Article in En | MEDLINE | ID: mdl-22374460

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Antineoplastic Combined Chemotherapy Protocols / Receptor, ErbB-2 Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2012 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Antineoplastic Combined Chemotherapy Protocols / Receptor, ErbB-2 Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2012 Type: Article Affiliation country: Germany